121 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
such authorities may not agree that the data … false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare.
HIPAA, as amended
8-K
EX-99.1
QNRX
Quoin Pharmaceuticals Ltd
13 Mar 24
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
4:52pm
initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:06pm
benefits to the Company on the one hand, and the Placement Agent on the other hand, in connection with the Placement, (b) the relative fault of the parties … . The Company agrees that for the purposes of this paragraph the relative benefits to the Company and the Placement Agent of the contemplated transaction
424B3
z89kjbb1n0lq
8 Mar 24
Prospectus supplement
4:04pm
8-K
EX-10.1
al82e5evc9cos
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
8-K
EX-1.1
riio 6y37x9omza1yi
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
424B4
lto06m5
6 Mar 24
Prospectus supplement with pricing info
5:07pm
424B3
uv9m2w
4 Mar 24
Prospectus supplement
5:27pm
424B3
pbo8m10ijz5q9k
31 Jan 24
Prospectus supplement
12:00am
8-K
EX-10.1
5lpoy08nj8
30 Jan 24
Entry into a Material Definitive Agreement
4:05pm
424B3
zx0419 42
9 Nov 23
Prospectus supplement
5:15pm
8-K
EX-99.1
vkt12sa
9 Nov 23
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results
5:10pm